Nothing Special   »   [go: up one dir, main page]

LTPA2022015I1 - - Google Patents

Info

Publication number
LTPA2022015I1
LTPA2022015I1 LTPA2022015C LTPA2022015C LTPA2022015I1 LT PA2022015 I1 LTPA2022015 I1 LT PA2022015I1 LT PA2022015 C LTPA2022015 C LT PA2022015C LT PA2022015 C LTPA2022015 C LT PA2022015C LT PA2022015 I1 LTPA2022015 I1 LT PA2022015I1
Authority
LT
Lithuania
Application number
LTPA2022015C
Other languages
Lithuanian (lt)
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48795938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2022015(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LTPA2022015I1 publication Critical patent/LTPA2022015I1/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LTPA2022015C 2012-07-02 2022-11-25 LTPA2022015I1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261667058P 2012-07-02 2012-07-02
PCT/US2013/048999 WO2014008218A1 (en) 2012-07-02 2013-07-02 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

Publications (1)

Publication Number Publication Date
LTPA2022015I1 true LTPA2022015I1 (en) 2022-12-12

Family

ID=48795938

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP20192145.9T LT3795592T (en) 2012-07-02 2013-07-02 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
LTEP13737946.7T LT2867258T (en) 2012-07-02 2013-07-02 Optimization of human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
LTEP17177885.5T LT3275899T (en) 2012-07-02 2013-07-02 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
LTPA2022015C LTPA2022015I1 (en) 2012-07-02 2022-11-25

Family Applications Before (3)

Application Number Title Priority Date Filing Date
LTEP20192145.9T LT3795592T (en) 2012-07-02 2013-07-02 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
LTEP13737946.7T LT2867258T (en) 2012-07-02 2013-07-02 Optimization of human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
LTEP17177885.5T LT3275899T (en) 2012-07-02 2013-07-02 Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

Country Status (38)

Country Link
US (6) US9505839B2 (en)
EP (3) EP3275899B1 (en)
JP (5) JP6320376B2 (en)
KR (5) KR20230159625A (en)
CN (2) CN104411723B (en)
AR (3) AR091649A1 (en)
AU (4) AU2013286914B2 (en)
BR (1) BR112014032999B1 (en)
CA (2) CA2877746C (en)
CL (1) CL2014003637A1 (en)
CO (1) CO7170127A2 (en)
CY (3) CY1119563T1 (en)
DK (3) DK3795592T3 (en)
EA (2) EA202090227A1 (en)
ES (2) ES2638545T3 (en)
FI (2) FI3795592T3 (en)
FR (1) FR22C1057I2 (en)
HK (2) HK1207386A1 (en)
HR (2) HRP20171315T1 (en)
HU (3) HUE034553T2 (en)
IL (1) IL236517B (en)
LT (4) LT3795592T (en)
MX (2) MX365417B (en)
MY (3) MY197322A (en)
NL (1) NL301205I2 (en)
NO (2) NO2023008I1 (en)
NZ (1) NZ628528A (en)
PE (4) PE20191324A1 (en)
PH (1) PH12014502854B1 (en)
PL (2) PL2867258T3 (en)
PT (3) PT3275899T (en)
RS (2) RS61084B1 (en)
SG (2) SG11201408780XA (en)
SI (2) SI2867258T1 (en)
TN (1) TN2014000536A1 (en)
TW (6) TW202313688A (en)
UY (1) UY34887A (en)
WO (1) WO2014008218A1 (en)

Families Citing this family (472)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563193A (en) * 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1907424B1 (en) * 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
TWI507205B (en) 2009-03-25 2015-11-11 Genentech Inc Anti-fgfr3 antibodies and methods using same
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
AR091649A1 (en) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
US10344088B2 (en) * 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
SI3178849T1 (en) * 2013-09-20 2019-06-28 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
ME03527B (en) 2013-12-12 2020-04-20 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
SI3466949T1 (en) 2013-12-24 2021-03-31 Bristol-Myers Squibb Company Tricyclic compound as anticancer agents
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
TWI680138B (en) * 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
RS62788B1 (en) 2014-01-28 2022-02-28 Bristol Myers Squibb Co Anti-lag-3 antibodies to treat hematological malignancies
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CA2938193C (en) * 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
EP3116542A2 (en) 2014-03-12 2017-01-18 Yeda Research and Development Co., Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
LT3116909T (en) 2014-03-14 2020-02-10 Novartis Ag Antibody molecules to lag-3 and uses thereof
SI3122745T1 (en) 2014-03-24 2019-05-31 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
CN106535884A (en) 2014-06-06 2017-03-22 弗雷克萨斯生物科学公司 Immunoregulatory agents
EA037006B1 (en) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
TWI693232B (en) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
EP3177593A1 (en) 2014-08-06 2017-06-14 Novartis AG Quinolone derivatives as antibacterials
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
RU2718914C2 (en) 2014-09-13 2020-04-15 Новартис Аг Combined treatment methods using alk inhibitors
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN107205970A (en) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 Immunomodulator
AR102537A1 (en) 2014-11-05 2017-03-08 Flexus Biosciences Inc IMMUNOMODULATING AGENTS
ME03806B (en) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
ME03546B (en) 2014-12-16 2020-07-20 Novartis Ag Isoxazole hydroxamic acid compounds as lpxc inhibitors
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
AR103232A1 (en) 2014-12-22 2017-04-26 Bristol Myers Squibb Co TGFbR ANTAGONISTS
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
EP3250229B1 (en) 2015-01-29 2022-07-27 The Trustees of the University of Pennsylvania Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
MA41463A (en) 2015-02-03 2017-12-12 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3)
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CN107635583A (en) * 2015-02-19 2018-01-26 生物临床医疗公司 For the method for the treatment of cancer, composition and kit
KR20170122799A (en) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-beta Inhibitor
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
EP3277670A1 (en) 2015-04-03 2018-02-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
EA201792273A1 (en) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани COMPOSITIONS CONTAINING A COMBINATION OF ANTI-PD-1 ANTIBODIES AND OTHER ANTIBODIES
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10174024B2 (en) 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
CN111234027A (en) 2015-05-21 2020-06-05 哈普恩治疗公司 Trispecific binding proteins and methods of use
RS60792B1 (en) 2015-05-29 2020-10-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
EA201792623A1 (en) 2015-06-03 2018-04-30 Бостон Биомедикал, Инк. COMPOSITIONS CONTAINING CANCER STEM BONE INHIBITOR AND IMMUNOTHERAPEUTIC AGENT TO BE USED IN CANCER TREATMENT
EA039293B1 (en) * 2015-06-05 2021-12-30 Мерк Шарп И Доум Корп. Anti-lag3 antibodies and antigen-binding fragments
TWI773646B (en) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
JP2018526977A (en) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ Antibody against CD40 with enhanced agonist activity
JP2018521983A (en) 2015-07-16 2018-08-09 バイオカイン セラピューティックス リミテッド Compositions and methods for treating cancer
CN108348601B (en) * 2015-07-22 2022-05-17 索伦托药业有限公司 Antibody therapeutics that bind to LAG3
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
PE20181151A1 (en) 2015-07-30 2018-07-17 Macrogenics Inc BINDING MOLECULES TO PD-1 AND METHODS OF USE OF THE SAME
US20180250303A1 (en) 2015-08-25 2018-09-06 Bristol-Myers Squibb Company Tgf beta receptor antagonists
MX2018002610A (en) 2015-09-02 2018-09-27 Immutep Sas Anti-LAG-3 Antibodies.
EP3356416B1 (en) * 2015-09-29 2021-03-24 Shanghai Zhangjiang Biotechnology Co., Ltd Pd-1 antibodies and uses thereof
SG10202008325XA (en) 2015-10-02 2020-09-29 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CN108289951A (en) * 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 Anti- factor D antibody and conjugate
PE20181300A1 (en) 2015-11-02 2018-08-09 Five Prime Therapeutics Inc CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF CANCER
CN108350416A (en) 2015-11-09 2018-07-31 百时美施贵宝公司 The method for manipulating the metric attribute of the polypeptide generated in Chinese hamster ovary celI
JP6945456B2 (en) * 2015-11-13 2021-10-06 マクロジェニクス，インコーポレーテッド LAG-3 binding molecule and how to use it
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
EP3377532B1 (en) 2015-11-19 2022-07-27 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3376857B1 (en) 2015-11-20 2021-02-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
US11447553B2 (en) 2015-11-23 2022-09-20 Five Prime Therapeutics, Inc. FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EA201891178A1 (en) 2015-12-14 2019-01-31 Макродженикс, Инк. Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use
KR20180094036A (en) 2015-12-15 2018-08-22 브리스톨-마이어스 스큅 컴퍼니 CXCR4 receptor antagonist
RU2018123481A (en) * 2015-12-16 2020-01-20 Мерк Шарп И Доум Корп. ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US20170198040A1 (en) 2015-12-18 2017-07-13 Novartis Ag ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
EA039865B1 (en) 2016-01-11 2022-03-22 Универзитет Цюрих Immune-stimulating humanized monoclonal antibody against human interleukin-2 and fusion protein
CN109071447B (en) 2016-02-19 2022-04-22 诺华股份有限公司 Tetracyclic pyridinone compounds as antiviral agents
CA3016534A1 (en) * 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EA201891983A8 (en) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани COMBINED THERAPY BY ANTIBODIES TO CD73
WO2017163186A1 (en) 2016-03-24 2017-09-28 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
IL262359B (en) 2016-04-13 2022-09-01 Vivia Biotech Sl Ex vivo bite-activated t cells
BR112018071307A2 (en) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. human cd40 binding agonist antibodies and uses thereof
EP3452029A4 (en) 2016-05-04 2019-10-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2019516682A (en) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Indoleamine 2,3-dioxygenase inhibitors and methods of use thereof
US10323004B2 (en) 2016-05-04 2019-06-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2019522627A (en) 2016-05-04 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Indoleamine 2,3-dioxygenase inhibitor and method of use thereof
CN109311816A (en) 2016-05-04 2019-02-05 百时美施贵宝公司 The inhibitor and its application method of indole amine 2,3-dioxygenase
MA55697A (en) * 2016-05-18 2022-02-23 Boehringer Ingelheim Int ANTIBODY MOLECULES FOR THE TREATMENT OF CANCER
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3025019A1 (en) 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
CN109715196A (en) 2016-06-13 2019-05-03 转矩医疗股份有限公司 For promoting the composition and method of immune cell function
US10071973B2 (en) 2016-06-14 2018-09-11 Novartis Ag Crystalline isoxazole hydroxamic acid compounds
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
SG11201811064TA (en) 2016-06-20 2019-01-30 F Star Delta Ltd Binding molecules binding pd-l1 and lag-3
JP7261379B2 (en) 2016-06-20 2023-04-20 カイマブ・リミテッド Anti-PD-L1 antibody
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
MX2018015393A (en) 2016-06-23 2019-04-29 Jiangsu Hengrui Medicine Co Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof.
UA125216C2 (en) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Combination therapies
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3484516A4 (en) 2016-07-14 2020-03-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US20190292179A1 (en) 2016-07-21 2019-09-26 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
KR102340687B1 (en) * 2016-08-15 2021-12-16 국립대학법인 홋가이도 다이가쿠 anti-LAG-3 antibody
CN109843322A (en) 2016-08-26 2019-06-04 百时美施贵宝公司 The inhibitor and its application method of indole amine 2,3-dioxygenase
TW201811788A (en) 2016-09-09 2018-04-01 瑞士商諾華公司 Polycyclic pyridone compounds as antivirals
EP3515936A1 (en) 2016-09-23 2019-07-31 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
IL302808A (en) 2016-10-11 2023-07-01 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
KR20230136711A (en) * 2016-10-13 2023-09-26 치아타이 티안큉 파마수티컬 그룹 주식회사 Anti-lag-3 antibodies and compositions
WO2018073753A1 (en) 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
LT3551660T (en) 2016-12-07 2023-12-27 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
EP4310082A3 (en) 2017-01-20 2024-04-10 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
EA201991673A1 (en) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. LAB3-labeled RADIOACTIVE ISOTOPE ANTIBODIES FOR IMMUNO-PET VISUALIZATION
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
KR102144317B1 (en) * 2017-02-22 2020-08-18 아이-맵 바이오파마 유에스 리미티드 Anti-LAG-3 antibody and use thereof
WO2018183928A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
US20200031944A1 (en) 2017-03-31 2020-01-30 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
BR112019017329A2 (en) 2017-04-03 2020-04-14 Hoffmann La Roche immunoconjugates, one or more polynucleotides and vectors, methods for the production of an immunoconjugate, treatment of a disease and for the stimulation of the immune system, composition, use of the immunoconjugate, invention and uses of the composition
CN110392698B (en) 2017-04-05 2022-01-25 豪夫迈·罗氏有限公司 anti-LAG 3 antibodies
CN116375876A (en) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 Bispecific antibodies that specifically bind PD1 and LAG3
EP4116328A1 (en) 2017-04-05 2023-01-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination therapies targeting pd-1, tim-3, and lag-3
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
MX2019012431A (en) 2017-04-21 2020-08-03 Ikena Oncology Inc Indole ahr inhibitors and uses thereof.
US11760777B2 (en) 2017-04-26 2023-09-19 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
JP2020517695A (en) * 2017-04-27 2020-06-18 テサロ， インコーポレイテッド Antibody drugs against lymphocyte activation gene-3 (LAG-3) and their use
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
US20200385472A1 (en) 2017-04-28 2020-12-10 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
KR20190139216A (en) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Therapeutic Methods Using CD80 Extracellular Domain Polypeptides
UY37718A (en) 2017-05-05 2018-11-30 Novartis Ag 2-TRYCLINAL QUINOLINONES AS ANTIBACTERIAL AGENTS
EP3621642B1 (en) * 2017-05-10 2024-09-18 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against lag3 and uses thereof
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN113896792A (en) 2017-05-12 2022-01-07 哈普恩治疗公司 Mesothelin binding proteins
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3634417B1 (en) 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
US11807686B2 (en) 2017-05-30 2023-11-07 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
MX2019012076A (en) * 2017-05-30 2019-12-09 Bristol Myers Squibb Co Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody.
US20210340250A1 (en) * 2017-05-30 2021-11-04 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CA3065929A1 (en) 2017-06-01 2018-12-06 Michael Wayne SAVILLE Bispecific antibodies that bind cd123 and cd3
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
MX2019015885A (en) 2017-06-22 2020-09-10 Novartis Ag Antibody molecules to cd73 and uses thereof.
TW201904993A (en) 2017-06-22 2019-02-01 瑞士商諾華公司 Use of IL-1β binding antibody
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
CA3066747A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
CA3066789A1 (en) 2017-06-30 2019-01-03 Bristol-Myers Squibb Company Amorphous and crystalline forms of ido inhibitors
JP6896989B2 (en) * 2017-07-13 2021-06-30 ナンジン リーズ バイオラブズ カンパニー リミテッド Antibody-bound LAG-3 and its use
AU2018302283A1 (en) 2017-07-20 2020-02-06 Novartis Ag Dosage regimens of anti-LAG-3 antibodies and uses thereof
EP3658565B1 (en) 2017-07-28 2022-11-09 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
EP3668496A4 (en) 2017-08-17 2021-07-14 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
ES2977589T3 (en) 2017-08-18 2024-08-27 Cothera Bioscience Inc Polymorphic form of TG02
CA3073733A1 (en) 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anti-lag-3 antibodies and uses thereof
ES2945140T3 (en) 2017-08-31 2023-06-28 Bristol Myers Squibb Co Cyclic dinucleotides as anticancer agents
JP7316263B2 (en) 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
CN111051328B (en) 2017-08-31 2023-11-03 百时美施贵宝公司 Cyclic dinucleotides as anticancer agents
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein degraders and uses thereof
BR112020006860A2 (en) * 2017-10-05 2020-10-20 Daiichi Sankyo Company, Limited composition for depleting cytotoxic t cells
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR20220111743A (en) 2017-10-13 2022-08-09 하푼 테라퓨틱스, 인크. B cell maturation antigen binding proteins
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
EP3697801A1 (en) 2017-10-16 2020-08-26 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. Bite-activated car-t cells
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3704159A1 (en) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
KR20200085303A (en) 2017-11-06 2020-07-14 브리스톨-마이어스 스큅 컴퍼니 Isofuranone compounds useful as HPK1 inhibitors
KR20200089286A (en) 2017-11-16 2020-07-24 노파르티스 아게 Combination therapy
US20210079015A1 (en) 2017-11-17 2021-03-18 Novartis Ag Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
EP3717907A1 (en) 2017-11-30 2020-10-07 Novartis AG Bcma-targeting chimeric antigen receptor, and uses thereof
JP7348899B2 (en) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド Multispecific molecules and their uses
JP7489316B2 (en) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド FC-binding fragment having PD-LI antigen-binding site
EP3728266A1 (en) 2017-12-20 2020-10-28 Novartis AG Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
TW201927337A (en) * 2017-12-22 2019-07-16 大陸商江蘇恆瑞醫藥股份有限公司 LAG-3 antibody pharmaceutical composition and use thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
KR20200103761A (en) 2017-12-27 2020-09-02 브리스톨-마이어스 스큅 컴퍼니 Anti-CD40 antibody and uses thereof
CN109970856B (en) * 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 anti-LAG-3 antibodies and uses thereof
WO2019129136A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-pd-l1 antibody and uses thereof
WO2019129137A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-lag-3 antibody and uses thereof
CN115925943A (en) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 Anti-PD-L1 antibodies and uses thereof
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
JP7358361B2 (en) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Antibodies against TIM3 and their uses
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11655295B2 (en) 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
IL301089A (en) 2018-01-29 2023-05-01 Vertex Pharma Gcn2 inhibitors and uses thereof
IL276147B2 (en) 2018-01-29 2024-10-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
JP2021511793A (en) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibody containing an antigen binding site that binds to LAG3
JP2021511782A (en) 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Stabilized immunoglobulin domain
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
JP2021514982A (en) 2018-02-28 2021-06-17 ノバルティス アーゲー Indole-2-carbonyl compounds and their use for the treatment of hepatitis B
JP7250808B2 (en) 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
JP7438180B2 (en) 2018-03-20 2024-02-26 ウーシー バイオロジクス アイルランド リミテッド Novel anti-LAG-3 antibody polypeptide
PE20210290A1 (en) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc SIGHT BINDING ANTIBODIES AT ACID pH
KR20200135830A (en) 2018-03-23 2020-12-03 브리스톨-마이어스 스큅 컴퍼니 Antibodies against MICA and/or MICB and uses thereof
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
JP7104458B2 (en) 2018-04-02 2022-07-21 上海博威生物医薬有限公司 Lymphocyte activation gene-3 (LAG-3) -binding antibody and its use
CN110343178B (en) * 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 Anti-human LAG-3 monoclonal antibody and application thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN112292128A (en) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 EP4 inhibitors and uses thereof
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
SG11202010159RA (en) 2018-04-18 2020-11-27 Xencor Inc Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112512578A (en) 2018-06-01 2021-03-16 诺华股份有限公司 Administration of bispecific antibodies that bind to CD123 and CD3
SG11202010579XA (en) 2018-06-01 2020-12-30 Novartis Ag Binding molecules against bcma and uses thereof
JP2021527082A (en) 2018-06-11 2021-10-11 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ New immune checkpoint inhibitor
CN110606892B (en) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 LAG-3 antibody with high affinity and high biological activity and application thereof
CN110615840A (en) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 Fully human anti-LAG-3 antibodies and uses thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
HRP20230627T1 (en) 2018-06-27 2023-09-29 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
AU2019291794B2 (en) 2018-06-27 2022-06-16 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as T cell activators
US11945864B2 (en) 2018-06-29 2024-04-02 Y-Biologics Inc. Monoclonal antibody specifically binding to LAG-3 and use thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
BR122022012697B1 (en) 2018-07-10 2023-04-04 Novartis Ag USES OF 3-(5-HYDROXY-1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6- DIONE DERIVATIVES, AND KIT
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
US11993584B2 (en) 2018-07-18 2024-05-28 Arcus Biosciences, Inc. Solid forms of an azolopyrimidine compound
CN112584865A (en) 2018-07-20 2021-03-30 表面肿瘤学公司 anti-CD 112R compositions and methods
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20210355113A1 (en) 2018-07-23 2021-11-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
JP2021532143A (en) * 2018-07-26 2021-11-25 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company LAG-3 combination therapy for the treatment of cancer
CN110172099B (en) * 2018-08-16 2020-03-03 上海健信生物医药科技有限公司 anti-LAG-3 humanized monoclonal antibody molecule, antigen binding fragment and medical application thereof
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2022500499A (en) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド EIF4E Inhibitors and Their Use
TWI838401B (en) 2018-09-12 2024-04-11 瑞士商諾華公司 Antiviral pyridopyrazinedione compounds
JP7512210B2 (en) 2018-09-21 2024-07-08 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド Novel interleukin 2 and uses thereof
CA3098765A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
JP2022504839A (en) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド Anti-LAP antibody mutants and their use
PE20211055A1 (en) 2018-10-12 2021-06-07 Xencor Inc IL-15 / IL-15 RALPHA F C FUSION PROTEINS TARGETING PD-1 AND USES IN COMBINATION THERAPIES OF THE SAME
JP2022512750A (en) * 2018-10-19 2022-02-07 ブリストル－マイヤーズ スクイブ カンパニー Combination therapy for melanoma
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
MX2021005708A (en) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof.
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN113490499A (en) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 CDK9 inhibitors and polymorphs thereof as active agents for the treatment of cancer
CN113438961A (en) 2018-12-20 2021-09-24 Xencor股份有限公司 Targeting heterodimeric Fc fusion proteins containing IL-15/IL-15R α and NKG2D antigen binding domains
CN113271945A (en) 2018-12-20 2021-08-17 诺华股份有限公司 Dosing regimens and pharmaceutical combinations comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128620A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
AU2019406840A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
US20220054524A1 (en) 2018-12-21 2022-02-24 Onxeo New conjugated nucleic acid molecules and their uses
EP3924351A4 (en) 2019-02-12 2022-12-21 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN111620949A (en) 2019-02-28 2020-09-04 三生国健药业（上海）股份有限公司 Antibodies that bind human LAG-3, methods of making, and uses thereof
US20220152179A1 (en) 2019-03-19 2022-05-19 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
JP7547360B2 (en) 2019-03-22 2024-09-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Compositions Comprising PKM2 Modulators and Methods of Treatment Using Same
MA55516A (en) 2019-03-26 2022-02-09 Univ Michigan Regents DEGRADING AGENTS, SMALL MOLECULES, OF STAT3
EP3947403A1 (en) 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
TW202106676A (en) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat degraders and uses thereof
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
US20220249659A1 (en) 2019-05-13 2022-08-11 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
KR20220016155A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
JP2022536728A (en) 2019-06-12 2022-08-18 ヴァンダービルト ユニバーシティー Dibenzylamines as amino acid transport inhibitors
WO2020252353A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CA3144116A1 (en) * 2019-06-24 2020-12-30 Innovent Biologics (Suzhou) Co., Ltd. Formulation comprising anti-lag-3 antibody, method for preparing same and use thereof
EP3994132A1 (en) 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
IT201900011676A1 (en) 2019-07-12 2021-01-12 St Superiore Di Sanita Human recombinant antibody against the LAG3 membrane receptor, its medical and diagnostic uses.
CN114127073B (en) 2019-07-16 2024-05-31 密歇根大学董事会 Imidazopyrimidines as EED inhibitors and use thereof
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021041664A1 (en) 2019-08-27 2021-03-04 The Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
AR119821A1 (en) 2019-08-28 2022-01-12 Bristol Myers Squibb Co SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
BR112022004451A2 (en) 2019-09-13 2022-06-21 Nimbus Saturn Inc hpk1 antagonists and uses thereof
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
AU2020350689A1 (en) 2019-09-19 2022-03-31 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
AU2020348849A1 (en) 2019-09-19 2022-04-07 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
CN114667285A (en) 2019-09-26 2022-06-24 诺华股份有限公司 Antiviral pyrazolopyridinone compounds
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
WO2021072277A1 (en) * 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
TW202128757A (en) 2019-10-11 2021-08-01 美商建南德克公司 Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
TW202128166A (en) 2019-10-21 2021-08-01 瑞士商諾華公司 Combination therapies
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
CN114599372A (en) 2019-11-04 2022-06-07 阿斯利康(瑞典)有限公司 Combination therapy for the treatment of cancer
BR112022008191A2 (en) 2019-11-08 2022-07-12 Bristol Myers Squibb Co LAG-3 ANTAGONIST THERAPY FOR MELANOMA
MX2022005839A (en) 2019-11-19 2022-06-09 Bristol Myers Squibb Co Compounds useful as inhibitors of helios protein.
US11591339B2 (en) 2019-11-26 2023-02-28 Ikena Oncology, Inc. Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
MX2022006134A (en) 2019-11-26 2022-06-17 Bristol Myers Squibb Co Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoro quinolin-4-yl)cyclohexyl)propanamide.
TW202136251A (en) 2019-12-17 2021-10-01 美商凱麥拉醫療公司 Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
BR112022011902A2 (en) 2019-12-20 2022-09-06 Novartis Ag COMBINATION THERAPIES
MX2022007130A (en) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Substituted piperazine derivatives useful as t cell activators.
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds useful as t cell activators
AR120823A1 (en) 2019-12-23 2022-03-23 Bristol Myers Squibb Co SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS
US20230094758A1 (en) 2019-12-23 2023-03-30 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
KR20220151160A (en) 2019-12-23 2022-11-14 카이메라 쎄라퓨틱스 인코포레이티드 SMARCA disintegrant and its uses
BR112022012220A2 (en) 2019-12-23 2022-09-13 Bristol Myers Squibb Co SUBSTITUTED PIPERAZINE QUINOLINONYL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
KR20230020379A (en) 2020-01-06 2023-02-10 하이파이바이오 (에이치케이) 리미티드 Anti-TNFR2 Antibodies and Uses Thereof
US20230054718A1 (en) 2020-01-07 2023-02-23 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
TW202140473A (en) 2020-01-15 2021-11-01 美商纜圖藥品公司 Map4k1 inhibitors
AU2021207348A1 (en) 2020-01-17 2022-08-11 Novartis Ag Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CN111205371B (en) * 2020-01-22 2022-03-29 北京吉尔麦迪生物医药科技有限公司 Antibody for resisting lymphocyte activating gene 3 and application
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN115485302A (en) 2020-03-09 2022-12-16 百时美施贵宝公司 Antibodies against CD40 with enhanced agonist activity
MX2022011602A (en) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Mdm2 degraders and uses thereof.
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
TW202140441A (en) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 Substituted oxoisoindoline compounds
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
AR122493A1 (en) 2020-06-02 2022-09-14 Arcus Biosciences Inc ANTI-TIGIT ANTIBODIES
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
AR122644A1 (en) 2020-06-19 2022-09-28 Onxeo NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES
KR20230027056A (en) 2020-06-23 2023-02-27 노파르티스 아게 Dosage regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
KR20230035576A (en) 2020-07-07 2023-03-14 비온테크 에스이 RNA for the treatment of HPV-positive cancer
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
IL300175A (en) 2020-07-30 2023-03-01 Kymera Therapeutics Inc Methods of treating mutant lymphomas
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3188996A1 (en) 2020-08-10 2022-02-17 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
US20230416364A1 (en) 2020-08-13 2023-12-28 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
CN116234931A (en) 2020-08-17 2023-06-06 拜斯科技术开发有限公司 Bicyclic conjugates with specificity for NECTIN-4 and uses thereof
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
MX2023002326A (en) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Cell localization signature and immunotherapy.
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
MX2023004493A (en) 2020-10-23 2023-05-10 Bristol Myers Squibb Co Lag-3 antagonist therapy for lung cancer.
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
KR20230131189A (en) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 TEAD inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
JP2024508207A (en) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ LTBR agonists in combination therapy against cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
CA3204091A1 (en) 2020-12-08 2022-06-16 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
CN114621344B (en) * 2020-12-10 2022-08-30 北京东方百泰生物科技股份有限公司 Purification method of anti-LAG-3 monoclonal antibody
EP4262986A1 (en) 2020-12-16 2023-10-25 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
JP2024503265A (en) 2020-12-28 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー Antibody compositions and methods of use thereof
US20240325554A1 (en) 2021-01-11 2024-10-03 Bicycle TX Limited Methods for treating cancer
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
WO2022167457A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CA3206499A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
WO2022171745A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2022187423A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Cereblon ligands
US20240190874A1 (en) 2021-03-03 2024-06-13 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
EP4301756A1 (en) 2021-03-05 2024-01-10 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
JP2024510176A (en) 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション MAP4K1 inhibitor
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117858719A (en) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 Methods of dosing and treatment using a combination of checkpoint inhibitor therapy and CAR T cell therapy
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022253450A1 (en) 2021-04-05 2023-11-16 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
MX2023011715A (en) 2021-04-06 2023-10-12 Bristol Myers Squibb Co Pyridinyl substituted oxoisoindoline compounds.
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
KR20230170039A (en) 2021-04-13 2023-12-18 뉴베일런트, 아이엔씨. Amino-substituted heterocycles for treating cancer with EGFR mutations
CA3215081A1 (en) 2021-04-16 2022-10-20 Alfredo C. Castro Mek inhibitors and uses thereof
EP4334307A1 (en) 2021-05-07 2024-03-13 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
WO2022246179A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl inhibitor compounds
EP4341261A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl compounds
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
AU2022312496A1 (en) 2021-07-14 2024-02-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
AR126453A1 (en) 2021-07-15 2023-10-11 Blueprint Medicines Corp MAP4K1 INHIBITORS
CN118103368A (en) 2021-08-25 2024-05-28 皮克医疗公司 EIF4E inhibitors and uses thereof
EP4392421A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202328090A (en) 2021-09-08 2023-07-16 美商雷度納製藥公司 Papd5 and/or papd7 inhibitors
KR20240083095A (en) * 2021-09-29 2024-06-11 아케소 바이오파마, 인크. Anti-LAG3 antibodies, pharmaceutical compositions and uses
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
IL312348A (en) 2021-10-29 2024-06-01 Arcus Biosciences Inc Inhibitors of hif-2alpha and methods of use thereof
CN118176214A (en) 2021-10-29 2024-06-11 百时美施贵宝公司 LAG-3 antagonist therapy of hematological cancers
KR20240133795A (en) 2021-12-16 2024-09-04 발레리오 테라퓨틱스 Novel conjugated nucleic acid molecules and uses thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
IL314050A (en) 2022-01-26 2024-09-01 Bristol Myers Squibb Co Combination therapy for hepatocellular carcinoma
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
TW202342474A (en) 2022-02-14 2023-11-01 美商基利科學股份有限公司 Antiviral pyrazolopyridinone compounds
MX2024010310A (en) 2022-02-25 2024-08-28 Bristol Myers Squibb Co Combination therapy for colorectal carcinoma.
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
AU2023236289A1 (en) 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN118871451A (en) 2022-03-18 2024-10-29 百时美施贵宝公司 Method for isolating polypeptides
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN114874324B (en) * 2022-05-13 2023-02-03 苏州旭光科星抗体生物科技有限公司 Enzyme-linked immunoassay kit for detecting content of soluble LAG-3 protein and application thereof
TW202404581A (en) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek inhibitors and uses thereof
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
TW202415650A (en) 2022-08-02 2024-04-16 英商利米那生物科技有限公司 Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
TW202417439A (en) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 Bicyclic tetrahydrothiazepine derivatives
WO2024059142A1 (en) 2022-09-14 2024-03-21 Arcus Biosciences, Inc. Dispersions of etrumadenant
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en) 2022-10-20 2024-04-25 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
WO2024089418A1 (en) 2022-10-24 2024-05-02 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN115819595B (en) * 2023-01-03 2023-05-16 上海百英生物科技股份有限公司 anti-LAG3 nano antibody and preparation method and application thereof
WO2024150017A1 (en) 2023-01-13 2024-07-18 Akrivia Biomedics Limited Method of profiling diseases
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024192033A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1081681A (en) 1910-08-31 1913-12-16 Otis Elevator Co Alternating-current-motor control.
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
FR2656800B1 (en) 1990-01-08 1992-05-15 Roussy Inst Gustave NEW PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, DNA SEQUENCE ENCODING THESE PROTEINS AND PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5762905A (en) 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
JP3919830B2 (en) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 Anti-feline herpesvirus-1 recombinant antibody and gene fragment encoding the antibody
JPH08509612A (en) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド Transgenic non-human animal capable of producing heterologous antibody
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
WO1995018634A1 (en) 1994-01-04 1995-07-13 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
MX9605365A (en) 1994-05-06 1997-12-31 Roussy Inst Gustave Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody.
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
ATE227586T1 (en) 1995-07-21 2002-11-15 Applied Research Systems METHOD FOR DETECTION, IDENTIFICATION, ISOLATION, SELECTIVE LABELING AND TARGETED DETECTION OF TH1 LYMPHOCYTES USING LAG-3 PROTEIN
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2002502324A (en) 1996-03-07 2002-01-22 イーストマン ケミカル カンパニー Near infrared fluorescent security thermal transfer printing and marking ribbon
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
IL130123A (en) 1996-11-28 2007-07-24 Roussy Inst Gustave Mutants of the lag-3 protein, their expression and use and method for their production
KR100481230B1 (en) 1996-11-29 2005-04-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation(LAG-3)
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (en) 1998-04-20 2010-04-01 Glycart Biotechnology Ag GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODY-DEPENDENT CELL-EMITTED CYTOTOXICITY
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
US6951646B1 (en) 1998-07-21 2005-10-04 Genmab A/S Anti hepatitis C virus antibody and uses thereof
CN1328571B (en) 1998-12-23 2016-08-31 辉瑞大药厂 The human monoclonal antibodies of anti-CTLA-4
KR20060067983A (en) 1999-01-15 2006-06-20 제넨테크, 인크. Polypeptide variants with altered effector function
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DK2270147T4 (en) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd METHOD OF MONITORING THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
MXPA02001877A (en) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd1, a receptor for b74, and uses therefor.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
ES2609016T3 (en) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Antibodies that bind immunospecifically to BLyS
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
ES2405944T3 (en) 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
US7538206B2 (en) 2001-02-22 2009-05-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
DE60227067D1 (en) 2001-05-11 2008-07-24 Kirin Pharma Kk ARTIFICIAL HUMAN CHROMOSOME WITH THE GENE FOR THE LAMBDA LIGHT CHAIN OF HUMAN ANTIBODIES
CA2448319C (en) 2001-05-31 2010-07-27 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
ATE519779T1 (en) 2001-09-19 2011-08-15 Roussy Inst Gustave PROTEINS AND PEPTIDES BINDING TO THE GLU-PRO MOTIV, THERAPEUTIC COMPOSITIONS CONTAINING THEM AND THEIR APPLICATIONS
PT1436404E (en) 2001-09-19 2009-12-16 Alexion Pharma Inc Engineered templates and their use in single primer amplification
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
MXPA04010092A (en) 2002-04-16 2004-12-13 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
ATE481985T1 (en) 2002-07-03 2010-10-15 Ono Pharmaceutical Co IMMUNOPOTENTATING COMPOSITIONS
JP2006517785A (en) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of immune related diseases
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
PT1897548E (en) 2003-02-28 2013-11-19 Univ Johns Hopkins T cell regulation
WO2005034733A2 (en) 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
PL1711207T3 (en) * 2003-12-10 2013-08-30 Squibb & Sons Llc Interferon alpha antibodies and their uses
NZ549872A (en) 2004-04-13 2009-09-25 Hoffmann La Roche Anti-P-selectin antibodies
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
EP1747021B1 (en) 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EA014182B1 (en) 2004-07-20 2010-10-29 Симфоген А/С Anti-rhesus d recombinant polyclonal antibody composition, method for manufacturing thereof and use thereof
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
AU2005292227A1 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating CD30 positive lymphomas
HUE039237T2 (en) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-h1 and pd-1 in treatment of renal cell carcinoma
KR101291640B1 (en) 2005-02-18 2013-08-05 메다렉스, 엘.엘.시. Monoclonal antibodies against prostate specific membrane antigen(psma) lacking in fucosyl residues
MX2007010603A (en) 2005-03-23 2007-10-18 Pfizer Prod Inc Therapy of prostate cancer with ctla4 antibodies and hormonal therapy.
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
RS52100B (en) 2005-10-26 2012-06-30 Medarex, Inc. Methods and compounds for preparing cc-1065 analogs
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1966241A2 (en) 2005-12-05 2008-09-10 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
JP5382692B2 (en) 2006-07-10 2014-01-08 学校法人藤田学園 Antibody classification method, antigen identification method, antibody or antibody set acquisition method, antibody panel preparation method, and antibody or antibody set and use thereof
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
DK2059535T3 (en) * 2006-08-18 2014-01-13 Novartis Ag PRLR-SPECIFIC ANTIBODY AND APPLICATIONS THEREOF
CL2007003622A1 (en) 2006-12-13 2009-08-07 Medarex Inc Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
AU2008218766A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
WO2008121616A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibodies with decreased deamidation profiles
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
KR20100054780A (en) 2007-06-18 2010-05-25 엔.브이.오가논 Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8476419B2 (en) 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
DK2195017T3 (en) 2007-10-01 2015-01-19 Bristol Myers Squibb Co Human antibodies that bind mesothelin, and uses thereof
AR069747A1 (en) 2007-11-30 2010-02-17 Medarex Inc ANTI-B7H4 MONOCLONAL ANTIBODY CONJUGATE - PHARMACO AND METHODS OF USE
JP2011505146A (en) 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー Monoclonal antibody-partner molecule complex directed to protein tyrosine kinase 7 (PTK7)
AR072999A1 (en) * 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
MX2011002252A (en) 2008-08-25 2011-06-24 Amplimmune Inc Compositions of pd-1 antagonists and methods of use.
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
KR20200047793A (en) 2008-12-09 2020-05-07 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
DK2454284T3 (en) * 2009-07-15 2018-07-02 Aimm Therapeutics Bv GRAM POSITIVE BACTERIA-SPECIFIC BINDING COMPOUNDS
PL3279215T3 (en) 2009-11-24 2020-06-29 Medimmune Limited Targeted binding agents against b7-h1
KR101842301B1 (en) * 2010-07-14 2018-03-26 머크 샤프 앤드 돔 코포레이션 Anti-addl monoclonal antibody and uses thereof
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
US10344088B2 (en) 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
JP2016531907A (en) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Combination of CD27 agonist and immune checkpoint inhibition for immune stimulation
SI3178849T1 (en) 2013-09-20 2019-06-28 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
RS62788B1 (en) 2014-01-28 2022-02-28 Bristol Myers Squibb Co Anti-lag-3 antibodies to treat hematological malignancies
EA201792273A1 (en) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани COMPOSITIONS CONTAINING A COMBINATION OF ANTI-PD-1 ANTIBODIES AND OTHER ANTIBODIES
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3795592B1 (en) 2024-07-24
MY169383A (en) 2019-03-26
BR112014032999A2 (en) 2017-08-01
CA2877746C (en) 2022-07-19
KR20150023909A (en) 2015-03-05
TW202118789A (en) 2021-05-16
US20170137514A1 (en) 2017-05-18
PT3275899T (en) 2020-11-17
LT3795592T (en) 2024-09-25
PE20150221A1 (en) 2015-02-19
FR22C1057I1 (en) 2023-01-06
EP2867258A1 (en) 2015-05-06
EP3275899A1 (en) 2018-01-31
PE20191324A1 (en) 2019-09-24
HUE034553T2 (en) 2018-02-28
PT3795592T (en) 2024-09-17
US9505839B2 (en) 2016-11-29
LT3275899T (en) 2020-12-10
TN2014000536A1 (en) 2016-03-30
TWI662046B (en) 2019-06-11
JP6320376B2 (en) 2018-05-09
PE20191759A1 (en) 2019-12-12
CY1119563T1 (en) 2018-03-07
EA201590138A1 (en) 2015-07-30
TWI576355B (en) 2017-04-01
HRP20171315T1 (en) 2017-10-20
KR20210102485A (en) 2021-08-19
TWI617581B (en) 2018-03-11
MX2019006411A (en) 2019-08-14
HRP20201852T1 (en) 2021-01-08
FR22C1057I2 (en) 2023-12-15
AR129651A2 (en) 2024-09-18
HK1207386A1 (en) 2016-01-29
FI3795592T3 (en) 2024-10-01
MX365417B (en) 2019-06-03
SG10201610960YA (en) 2017-02-27
CY1123609T1 (en) 2022-03-24
HRP20201852T8 (en) 2021-06-25
FIC20230009I1 (en) 2023-02-09
AU2013286914A1 (en) 2015-01-29
US11345752B2 (en) 2022-05-31
HK1249535A1 (en) 2018-11-02
UY34887A (en) 2013-12-31
CY2022035I2 (en) 2023-01-27
CL2014003637A1 (en) 2015-03-27
CN104411723A (en) 2015-03-11
EA035013B1 (en) 2020-04-17
US20230077348A1 (en) 2023-03-16
NL301205I2 (en) 2023-05-24
MY197544A (en) 2023-06-22
JP2015527880A (en) 2015-09-24
NO2023008I1 (en) 2023-02-07
AU2021225177A1 (en) 2021-09-30
AU2017221874B2 (en) 2019-05-02
HUS2300002I1 (en) 2023-01-28
PE20241623A1 (en) 2024-08-07
KR20230159625A (en) 2023-11-21
TW202313688A (en) 2023-04-01
PH12014502854A1 (en) 2015-02-23
US20140093511A1 (en) 2014-04-03
WO2014008218A1 (en) 2014-01-09
US20180371087A1 (en) 2018-12-27
TW201938198A (en) 2019-10-01
AU2017221874A1 (en) 2017-09-21
PH12014502854B1 (en) 2015-02-23
KR20200075891A (en) 2020-06-26
US10377824B2 (en) 2019-08-13
KR20220150417A (en) 2022-11-10
PT2867258T (en) 2017-08-31
SI3275899T1 (en) 2020-11-30
IL236517B (en) 2018-06-28
CY2022035I1 (en) 2023-01-05
CA3161329A1 (en) 2014-01-09
CA2877746A1 (en) 2014-01-09
TW201406784A (en) 2014-02-16
NO2023020I1 (en) 2023-05-03
IL236517A0 (en) 2015-02-26
TWI771721B (en) 2022-07-21
US10266591B2 (en) 2019-04-23
LT2867258T (en) 2017-09-11
RS56398B1 (en) 2017-12-29
HUE052406T2 (en) 2021-04-28
PL3795592T3 (en) 2024-10-07
CN108101991B (en) 2022-02-11
ES2831406T3 (en) 2021-06-08
MX2015000116A (en) 2015-04-14
AU2019204803A1 (en) 2019-07-25
DK3795592T3 (en) 2024-10-14
AR091649A1 (en) 2015-02-18
JP2022064901A (en) 2022-04-26
JP2020103301A (en) 2020-07-09
AU2019204803C1 (en) 2023-06-29
MY197322A (en) 2023-06-13
DK2867258T3 (en) 2017-10-02
TW201831515A (en) 2018-09-01
JP6668405B2 (en) 2020-03-18
TW201726743A (en) 2017-08-01
ES2638545T3 (en) 2017-10-23
EA202090227A1 (en) 2020-05-31
EP3795592A1 (en) 2021-03-24
US20190256594A1 (en) 2019-08-22
US20150307609A1 (en) 2015-10-29
KR102290633B1 (en) 2021-08-19
PL2867258T3 (en) 2017-11-30
RS61084B1 (en) 2020-12-31
NL301205I1 (en) 2023-04-19
CO7170127A2 (en) 2015-01-28
SI2867258T1 (en) 2017-10-30
JP7009531B2 (en) 2022-02-10
SG11201408780XA (en) 2015-01-29
JP2018126149A (en) 2018-08-16
KR102126596B1 (en) 2020-06-24
CN108101991A (en) 2018-06-01
AR125268A2 (en) 2023-06-28
BR112014032999B1 (en) 2022-10-18
AU2013286914B2 (en) 2017-06-29
EP3275899B1 (en) 2020-08-26
NZ628528A (en) 2016-07-29
JP2024041966A (en) 2024-03-27
CN104411723B (en) 2018-01-30
TWI701045B (en) 2020-08-11
KR102461102B1 (en) 2022-10-31
EP2867258B1 (en) 2017-06-28
AU2019204803B2 (en) 2021-06-10
DK3275899T3 (en) 2020-11-30

Similar Documents

Publication Publication Date Title
BR112014017635A2 (en)
BR112014017659A2 (en)
BR112014017646A2 (en)
AR092201A1 (en)
BR112014017638A2 (en)
BR122020018119A2 (en)
BR112013027865A2 (en)
BR112014017634A2 (en)
BR112014017644A2 (en)
BR112014017588A2 (en)
BR112014017647A2 (en)
BR112014013184A8 (en)
BR112014017630A2 (en)
BR112014017652A2 (en)
BR112014017621A2 (en)
BR112014017622A2 (en)
BR112014017627A2 (en)
BR112014017623A2 (en)
BR112014017631A2 (en)
BR112014017641A2 (en)
BR112014017816A2 (en)
BR112014017636A2 (en)
BR112015014865A2 (en)
BR112014017667A2 (en)
BR112014017671A2 (en)